Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- Photoenhancer FDA class
- How it’s given
- “In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).”In the company’s words, NCT03067051 on ClinicalTrials.gov
- Tested for
- Recurrent Prostate Cancer
- Main trialPhase 1/2
- “The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.”In the company’s words, NCT03067051 on ClinicalTrials.gov
Other drugs for Recurrent Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone AcetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamideAstellas · Pfizer · Phase 3
- MevrometostatPfizer · Phase 3
Coming up1
- 31 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Jul 2027 | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | |
| Phase 2Authorised | not given | SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026